144 related articles for article (PubMed ID: 12793378)
1. Safeguards for gene therapy trials.
FDA Consum; 2003; 37(3):5. PubMed ID: 12793378
[No Abstract] [Full Text] [Related]
2. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
Couzin J; Kaiser J
Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
[No Abstract] [Full Text] [Related]
3. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
4. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
Kaiser J
Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
[No Abstract] [Full Text] [Related]
5. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
6. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
European Society of Gene Therapy
J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
[No Abstract] [Full Text] [Related]
7. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
8. Occurrence of leukaemia following gene therapy of X-linked SCID.
Kohn DB; Sadelain M; Glorioso JC
Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
[TBL] [Abstract][Full Text] [Related]
9. Temporary halt on gene therapy trials.
FDA Consum; 2003; 37(2):6. PubMed ID: 12715756
[No Abstract] [Full Text] [Related]
10. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
11. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
12. Gene therapists hopeful as trials resume with childhood disease.
Check E
Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
[No Abstract] [Full Text] [Related]
13. Gene therapy. RAC's advice: proceed with caution.
Kaiser J
Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
[No Abstract] [Full Text] [Related]
14. Cancer fears cast doubts on future of gene therapy.
Check E
Nature; 2003 Feb; 421(6924):678. PubMed ID: 12610583
[No Abstract] [Full Text] [Related]
15. Cancer risk prompts US to curb gene therapy.
Check E
Nature; 2003 Mar; 422(6927):7. PubMed ID: 12621402
[No Abstract] [Full Text] [Related]
16. Clinical applications of gene therapy.
Carter B; Kohn DB
Curr Opin Mol Ther; 2000 Aug; 2(4):360-1. PubMed ID: 11249765
[No Abstract] [Full Text] [Related]
17. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
18. The trials of gene therapy.
Nature; 2002 Nov; 420(6912):107. PubMed ID: 12432344
[No Abstract] [Full Text] [Related]
19. Gene-therapy trials to restart following cancer risk review.
Check E
Nature; 2005 Mar; 434(7030):127. PubMed ID: 15758959
[No Abstract] [Full Text] [Related]
20. LMO2 and gene therapy for severe combined immunodeficiency.
Stone BD
N Engl J Med; 2004 Jun; 350(24):2526-7; author reply 2526-7. PubMed ID: 15195349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
